The Bipolar Depression market report also offers comprehensive insights into the Bipolar Depression market size, share, Bipolar Depression epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Bipolar Depression market size growth forward.
Some of the key highlights from the Bipolar Depression Market Insights Report:
Several key pharmaceutical companies, including Allergan (AbbVie)/Gedeon Richter, Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma), Intra-Cellular Therapies, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), Lundbeck/Otsuka Pharmaceutical, Celon Pharma, COMPASS Pathways, and others, are developing novel products to improve the Bipolar Depression treatment outlook.
In January 2025, Johnson & Johnson and Intra-Cellular Therapies announced a definitive agreement in which Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies, a biopharmaceutical company focused on developing and commercializing treatments for CNS disorders, for $132.00 per share in cash, amounting to an equity value of approximately $14.6 billion.
In December 2024, NRx Pharmaceuticals submitted the first section of its New Drug Application (NDA) for NRX-100 (ketamine) to the FDA. NRX-100, which received Fast Track Designation in 2017, is being developed in combination with NRX-101 (D-cycloserine/lurasidone) for the treatment of suicidal bipolar depression.
According to DelveInsight’s estimates, the total prevalent cases of Bipolar Depression in the 7MM were approximately 3.6 million in 2023, with severe cases comprising the majority (~75%) of the total cases.
DelveInsight’s consultants estimate that Bipolar II Disorder accounted for the highest proportion of cases, making up nearly 60% of type-specific diagnosed prevalent cases of bipolar depression in the 7MM in 2023.
Several medications have received approval from the U.S. Food and Drug Administration (FDA) for the treatment of acute bipolar depression. The olanzapine‐fluoxetine combination (OFC) was the first to receive approval in 2003, followed by quetiapine in 2006. In 2013, LATUDA (lurasidone) was approved as both a monotherapy and an adjunct to lithium or valproate for bipolar I depression. Cariprazine received approval in 2019, while CAPLYTA (lumateperone) was approved in 2021.
The United States holds the largest market share for bipolar depression, accounting for approximately 85% compared to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Among the currently marketed therapies, CAPLYTA (lumateperone) is projected to achieve the highest market size in the 7MM by 2034.
In April 2024, NRx Pharmaceuticals announced encouraging results from a Phase IIb/III clinical trial comparing NRX-101 to lurasidone for the treatment of suicidal bipolar depression. The findings suggested a promising, though not yet statistically significant, 33% reduction in suicidality along with a 70% reduction in symptoms of akathisia (P=0.076).
As per DelveInsight analysis, the Bipolar Depression market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Bipolar Depression Market Landscape
Bipolar Depression Overview
Bipolar disorder is a condition characterized by abnormal fluctuations in mood, energy, activity levels, concentration, and the ability to perform daily tasks. It encompasses various types, including Bipolar I, Bipolar II, Cyclothymia, mixed features, and rapid cycling. Within the broader category of Bipolar Disorder, bipolar depression presents a significant clinical challenge. Despite treatment, depression remains the predominant symptom, contributing to increased morbidity and mortality due to coexisting medical conditions and a heightened risk of suicide.
Currently, there is no definitive diagnostic test for Bipolar Disorder. Diagnosis typically involves a combination of physical examination, psychiatric evaluation, mood tracking, and assessment based on established diagnostic criteria. The bipolar depression report provides an in-depth overview of the condition’s pathophysiology, diagnostic methods, and a comprehensive treatment algorithm. It also offers insights into real-world patient experiences, covering the journey from initial symptom onset to diagnosis and the full course of treatment.
Do you know the treatment paradigms for different countries? Download our Bipolar Depression Market Sample Report
Bipolar Depression Epidemiology Insights
According to DelveInsight’s estimates, the United States accounted for approximately 70% of the total diagnosed prevalent cases of bipolar depression in the 7MM in 2023.
Within the U.S., severe cases made up the majority, representing around 75% of the total cases based on severity.
Bipolar Depression Epidemiology Segmentation
DelveInsight’s Bipolar Depression market report is prepared on the basis of an epidemiology model. It offers comprehensive insights to the Bipolar Depression historical patient pools and forecasted Bipolar Depression patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Bipolar Depression Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:
Bipolar Depression Prevalence
Age-Specific Bipolar Depression Prevalence
Gender-Specific Bipolar Depression Prevalence
Diagnosed and Treatable Cases of Bipolar Depression
Visit for more @ Bipolar Depression Epidemiological Insights
Bipolar Depression Market Outlook
Leading companies in the Bipolar Disorder market, including NeuroRx and COMPASS Pathways, are actively evaluating their key drug candidates at various stages of clinical development, aiming to explore their potential in treating bipolar depression.
Among the 7MM, the United States held the largest market share for Bipolar Disorder in 2023, valued at approximately USD 2,300 million, followed by Germany and Italy.
By 2034, NRX-100 and NRX-101 are expected to secure a significant market share for Bipolar Disorder across the 7 major markets.
Within the EU4 and the UK, Germany accounted for the highest market share (~30%) in 2023.
By 2034, CAPLYTA (lumateperone) is anticipated to dominate the Bipolar Disorder market among currently available therapies in the 7MM.
Bipolar Disorder Marketed Drugs
VRAYLAR (Cariprazine): Allergan (AbbVie)/Gedeon Richter
LYBALVI (olanzapine, samidorphan L-malate): Alkermes
Bipolar Depression Emerging Drugs
COMP 360 (Psilocybin): COMPASS Pathways
NRX-100 and NRX-101: NeuroRx
Bipolar Depression Key Companies
Allergan (AbbVie)/Gedeon Richter, Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma), Intra-Cellular Therapies, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), Lundbeck/Otsuka Pharmaceutical, Celon Pharma, COMPASS Pathways, and others
For more information, visit Bipolar Depression Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Bipolar Depression Market Report:
11 Years Forecast
7MM Coverage
Descriptive overview of Bipolar Depression, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Bipolar Depression epidemiology in the 7MM
Bipolar Depression marketed and emerging therapies
Bipolar Depression companies
Bipolar Depression market drivers and barriers
Table of Contents:
1 Bipolar Depression Market Key Comprehensive Insights
2 Bipolar Depression Market Report Introduction
3 Competitive Intelligence Analysis for Bipolar Depression
4 Bipolar Depression Market Analysis Overview at a Glance
5 Executive Summary of Bipolar Depression
6 Bipolar Depression Epidemiology and Market Methodology
7 Bipolar Depression Epidemiology and Patient Population
8 Bipolar Depression Patient Journey
9 Bipolar Depression Treatment Algorithm, Bipolar Depression Current Treatment, and Medical Practices
10 Key Endpoints in Bipolar Depression Clinical Trials
11 Bipolar Depression Marketed Therapies
12 Bipolar Depression Emerging Therapies
13 Bipolar Depression: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Bipolar Depression
16 Bipolar Depression Market Key Opinion Leaders Reviews
18 Bipolar Depression Market Drivers
19 Bipolar Depression Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Bipolar Depression Epidemiology 2034
DelveInsight’s “Bipolar Depression – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Bipolar Depression epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Bipolar Depression Pipeline 2024
“Bipolar Depression Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Bipolar Depression market. A detailed picture of the Bipolar Depression pipeline landscape is provided, which includes the disease overview and Bipolar Depression treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
